Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1101-1120 of 1,694 trials

Alzheimer's Agitation: Masupirdine Study

We are investigating whether masupirdine can help reduce agitation symptoms in people with Alzheimer's. The study will compare its effects to a placebo over 12 weeks.

Alzheimer's Disease3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Achondroplasia: Long-Term Study of Infigratinib

We are studying the long-term safety and effects of Infigratinib in children with Achondroplasia. The goal is to see how it impacts their growth and overall health.

Achondroplasia>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOrthopedics and TraumatologyPediatrics

Hypertrophic Cardiomyopathy: Sotagliflozin Study

We are investigating whether sotagliflozin can improve symptoms in people with hypertrophic cardiomyopathy. The study also looks at the safety of this treatment compared to a placebo.

Hypertrophic Cardiomyopathy6-12 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Preventing Constipation After Hip Surgery: Laxative Study

We are exploring which laxatives work best to prevent constipation in patients recovering from hip fracture surgery. This research aims to improve comfort and recovery after surgery.

Hip Fracture>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyOrthopedics and Traumatology

Rectal Cancer: Valproic Acid with Radiotherapy and Capecitabine

We are studying whether adding valproic acid to standard radiotherapy and capecitabine improves tumor response in patients with low to moderate risk rectal cancer before surgery. This trial also examines the impact on survival and quality of life.

Rectal CancerSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Opioid Dependency Treatment: Suboxone vs. Methadone

We are comparing the effectiveness of Suboxone and methadone in reducing opioid misuse for patients with chronic pain. The study also looks at how these treatments affect pain relief, well-being, and cognitive function.

Opioid Use Disorder>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicinePsychiatry

Locally Advanced Rectal Cancer: CApecitabine and Temozolomide Study

We are studying a new treatment combining capecitabine and temozolomide for patients with specific types of locally advanced rectal cancer. The goal is to see if this combination improves tumor response and surgical outcomes.

Locally Advanced Rectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Metastatic Breast Cancer: Next Generation Sequencing Oncochip

We are studying a new sequencing tool to help decide the best treatment for metastatic breast cancer patients. The goal is to see if it improves survival and response compared to standard chemotherapy.

Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Advanced Breast Cancer: Capivasertib and Fulvestrant Study

We are researching the combination of capivasertib and fulvestrant for patients with HR+/HER2- advanced breast cancer who have not responded to standard treatments. The study aims to evaluate treatment effectiveness and safety in real-world clinical practice.

Advanced Breast Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

TBR1-Related Neurocognitive Disorder: Lithium Carbonate Study

We are studying whether lithium carbonate can improve behavior and communication in patients with TBR1-related neurocognitive disorder. This trial will also assess the treatment's safety and overall impact on quality of life.

TBR1 Variant>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Relapsing-Remitting Multiple Sclerosis: Ozanimod Study

We are studying how ozanimod may help limit brain changes in people with relapsing-remitting multiple sclerosis. The trial looks at its effects on disease activity, cognition, fatigue, and quality of life.

Multiple Sclerosis>2 yearsMonitoring phase (IV)Neurology

HPV Infections: 2LPAPI® Treatment Study

We are testing a new treatment, 2LPAPI®, for people with high-risk HPV infections to see if it helps clear the virus better than a placebo. The study also looks at safety and how the treatment affects cervical cell health.

Human Papillomavirus Infection>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesGynecology and ObstetricsInfectious Diseases

Heart Failure and Kidney Disease: SENEKA Study

We are exploring a new treatment strategy for elderly patients with heart failure and chronic kidney disease to see if it helps manage potassium levels better. This study compares a potassium binder with standard medications to improve patient outcomes.

Chronic Heart Failure and Non-Dialysis Chronic Kidney Disease3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyInternal MedicineNephrology

RAR-Immune: Nivolumab + Ipilimumab vs. Pazopanib for Advanced Sarcoma

We are studying whether a combination of nivolumab and ipilimumab works better than pazopanib alone for patients with advanced rare sarcomas. This trial will help us understand treatment effectiveness and patient quality of life.

Advanced Rare Sarcomas>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

GIST Treatment: Lenvatinib vs. Placebo

We are evaluating whether lenvatinib can help patients with advanced GIST who did not respond to imatinib and sunitinib. This study compares its effects to a placebo to assess its potential benefits.

Metastatic Gastrointestinal Stromal Tumor (GIST)>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesOncology

Papillary Renal Cell Carcinoma: Axitinib with or without Pembrolizumab

We are studying the effects of axitinib alone versus axitinib combined with pembrolizumab in patients with advanced papillary renal cell carcinoma. This research aims to find out which treatment may work better as a first-line option.

Metastatic Renal Cell CarcinomaLocally Advanced or Metastatic Papillary Cell Carcinoma3-6 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyUrology

Vibegron for Children with Neurogenic Detrusor Overactivity

We are studying the safety and effectiveness of vibegron in children aged 2 to under 18 with neurogenic detrusor overactivity who use clean intermittent catheterization. This trial aims to understand how well the medication works and how it is processed in young patients.

Neurogenic Bladder1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPediatricsUrology

Ovarian Stimulation: Follitropin Delta and Dydrogesterone

We are studying a new ovarian stimulation method for egg donors to see if it produces similar results to traditional approaches. This research may help improve fertility treatments in the future.

Healthy Oocyte Donors1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and Obstetrics

Acute Myeloid Leukemia: Midostaurin and Gemtuzumab Ozogamicin

We are studying a new combination treatment for patients with acute myeloid leukemia to see if it is safe and effective alongside standard chemotherapy.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Breast Cancer: Genomics Guided Therapy Study

We are exploring whether a personalized treatment approach after surgery can improve outcomes for patients with early high-risk breast cancer. This study will assess survival rates and the safety of the new therapy.

Early Breast Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology